147 related articles for article (PubMed ID: 2257308)
21. Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
Kontoghiorghes GJ
Mol Pharmacol; 1986 Dec; 30(6):670-3. PubMed ID: 3785144
[TBL] [Abstract][Full Text] [Related]
22. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant.
Porter JB; Gyparaki M; Burke LC; Huehns ER; Sarpong P; Saez V; Hider RC
Blood; 1988 Nov; 72(5):1497-503. PubMed ID: 3179437
[TBL] [Abstract][Full Text] [Related]
23. Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits.
Kontoghiorghes GJ; Hoffbrand AV
Br J Haematol; 1986 Apr; 62(4):607-13. PubMed ID: 3964556
[TBL] [Abstract][Full Text] [Related]
24. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and evaluation of N-basic substituted 3-hydroxypyridin-4-ones: orally active iron chelators with lysosomotrophic potential.
Liu ZD; Khodr HH; Lu SL; Hider RC
J Pharm Pharmacol; 2000 Mar; 52(3):263-72. PubMed ID: 10757413
[TBL] [Abstract][Full Text] [Related]
26. Orally active alpha-ketohydroxypyridine iron chelators: effects on iron and other metal mobilisations.
Kontoghiorghes GJ
Acta Haematol; 1987; 78(2-3):212-6. PubMed ID: 3120474
[TBL] [Abstract][Full Text] [Related]
27. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores.
Zevin S; Link G; Grady RW; Hider RC; Peter HH; Hershko C
Blood; 1992 Jan; 79(1):248-53. PubMed ID: 1728313
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of oral deferiprone in acute iron poisoning.
Berkovitch M; Livne A; Lushkov G; Segal M; Talmor C; Bentur Y; Klein J; Koren G
Am J Emerg Med; 2000 Jan; 18(1):36-40. PubMed ID: 10674529
[TBL] [Abstract][Full Text] [Related]
29. Iron chelation therapy.
Hershko CM; Link GM; Konijn AM; Cabantchik ZI
Curr Hematol Rep; 2005 Mar; 4(2):110-6. PubMed ID: 15720959
[TBL] [Abstract][Full Text] [Related]
30. Characterisation of a novel oral iron chelator: 1-(N-Acetyl-6-Aminohexyl)-3-Hydroxy-2-Methylpyridin-4-one.
Pangjit K; Banjerdpongchai R; Phisalaphong C; Fucharoen S; Xie YY; Lu ZD; Hider RC; Srichairatanakool S
J Pharm Pharmacol; 2015 May; 67(5):703-13. PubMed ID: 25627251
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
Kontoghiorghes GJ
Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
[TBL] [Abstract][Full Text] [Related]
32. Oral iron-chelating therapy: the L1 experience.
al-Refaie FN; Hoffbrand AV
Baillieres Clin Haematol; 1994 Dec; 7(4):941-63. PubMed ID: 7881161
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of new iron chelators for clinical use.
Porter JB
Acta Haematol; 1996; 95(1):13-25. PubMed ID: 8604583
[TBL] [Abstract][Full Text] [Related]
34. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
[TBL] [Abstract][Full Text] [Related]
35. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
[TBL] [Abstract][Full Text] [Related]
36. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
Kontoghiorghes GJ
Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
[TBL] [Abstract][Full Text] [Related]
37. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.
Kontoghiorghes GJ; Aldouri MA; Sheppard L; Hoffbrand AV
Lancet; 1987 Jun; 1(8545):1294-5. PubMed ID: 2884415
[TBL] [Abstract][Full Text] [Related]
38. Clinical evaluation of the oral iron chelator deferiprone for the potential treatment of iron overload in bird species.
Whiteside DP; Barker IK; Mehren KG; Jacobs RM; Conlon PD
J Zoo Wildl Med; 2004 Mar; 35(1):40-9. PubMed ID: 15193072
[TBL] [Abstract][Full Text] [Related]
39. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.
Mazza P; Amurri B; Lazzari G; Masi C; Palazzo G; Spartera MA; Giua R; Sebastio AM; Suma V; De Marco S; Semeraro F; Moscogiuri R
Haematologica; 1998 Jun; 83(6):496-501. PubMed ID: 9676021
[TBL] [Abstract][Full Text] [Related]
40. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones.
Singh S; Epemolu RO; Dobbin PS; Tilbrook GS; Ellis BL; Damani LA; Hider RC
Drug Metab Dispos; 1992; 20(2):256-61. PubMed ID: 1352218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
